Skip to main content
SpringerLink
Log in

Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input

  • Published:
Pituitary Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

References

  1. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH (2022) and K K Y Ho “Clinical Biology of the Pituitary Adenoma " Endocr Rev 43(6):1003–1037

    Google Scholar 

  2. Calvanese F, Jacquesson T, Manet R, Vasiljevic A, Lasolle H, Ducray F, Raverot G (2022) Jouanneau. “Neoadjuvant B-Raf and mek inhibitor targeted therapy for adult Papillary Craniopharyngiomas: a New Treatment paradigm. Front Endocrinol (Lausanne) 13:882381

    Article  PubMed  Google Scholar 

  3. Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A (2018) “Correction To: Criteria for the Definition of Pituitary Tumor Centers of Excellence (Ptcoe): A Pituitary Society Statement.“ Pituitary 21, no. 6 : 663

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Skull Base and Pituitary Surgery, Pituitary Tumors Centers of Excellence (PTCOE) of Lyon and Center for Rare Pituitary Diseases (HYPO), Hôpital Pierre Wertheimer, “Groupement Hospitalier Est” Hospices Civils de Lyon, Lyon, France

    E. Jouanneau, F Calvanese & F Ducray

  2. Helsinki University Hospital, Helsinki, Finland

    F Calvanese

  3. Department of Neuro-oncology, Hospices Civils de Lyon, “Groupement Hospitalier Est”, Hôpital Pierre Wertheimer France, Lyon, France

    F Ducray

  4. Department of Endocrinology, Pituitary Tumors Centers of Excellence (PTCOE) of Lyon and Center for Rare Pituitary Diseases (HYPO), Hôpital Louis Pradel, “Groupement Hospitalier Est” Hospices Civils de Lyon, Lyon, France

    G. Raverot

Authors
  1. E. Jouanneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Calvanese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Ducray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Raverot
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Concept and design : E.J., G.R. and F.C. E.J. and F.C. wrote the main manuscript text but all the author have been participated to the conceptualization and revision of the presented work.

Corresponding author

Correspondence to F Calvanese.

Ethics declarations

Ethical approval

This study does not include human or animal subject. For this reason, no ethical approval is needed.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jouanneau, E., Calvanese, F., Ducray, F. et al. Pituitary Tumor Centers of Excellence (PTCOE) should now include neuro-oncologic input. Pituitary 26, 642–643 (2023). https://doi.org/10.1007/s11102-023-01348-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-023-01348-x

Search

Navigation